Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

SE Schild, JA Bonner, TG Shanahan, BJ Brooks… - International Journal of …, 2004 - Elsevier
PURPOSE: This Phase III study was performed to determine whether twice-daily (bid)
radiotherapy (RT) resulted in better survival than once-daily (qd) RT for patients with limited …

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

JA Bonner, JA Sloan, TG Shanahan… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: Because small-cell lung cancer is a rapidly proliferating tumor, it was
hypothesized that it may be more responsive to thoracic irradiation (TI) given twice-daily …

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

AT Turrisi, K Kim, R Blum, WT Sause… - … England Journal of …, 1999 - Mass Medical Soc
Background For small-cell lung cancer confined to one hemithorax (limited small-cell lung
cancer), thoracic radiotherapy improves survival, but the best ways of integrating …

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with …

NC Choi, JE Herndon 2nd, J Rosenman… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE An improvement in radiation dose schedule is necessary to increase local tumor
control and survival in limited-stage small-cell lung cancer. The goal of this study was to …

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for …

A Gregor, P Drings, J Burghouts, PE Postmus… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE To evaluate the effectiveness of alternating or sequential schedules of
cyclophosphamide, doxorubicin, and etoposide (CDE) chemotherapy and irradiation in …

Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.

DH Johnson, AT Turrisi, AY Chang, R Blum… - Journal of clinical …, 1993 - ascopubs.org
PURPOSE This pilot study was undertaken to determine the efficacy and feasibility of
alternating cisplatin and etoposide with multiple daily fractions of thoracic radiotherapy …

High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538

J Bogart, X Wang, G Masters, J Gao… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard
for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily …

Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung …

B Qiu, QW Li, JL Liu, Y Huang, QS Pang, ZF Zhu… - International Journal of …, 2021 - Elsevier
Purpose Chemotherapy and concurrent thoracic radiation therapy (CCTRT) followed by
prophylactic cranial irradiation (PCI) is the standard of care for limited-stage small cell lung …

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the …

M Takada, M Fukuoka, M Kawahara… - Journal of clinical …, 2002 - ascopubs.org
PURPOSE: To evaluate the optimal timing for thoracic radiotherapy (TRT) in limited-stage
small-cell lung cancer (LS-SCLC), the Lung Cancer Study Group of the Japan Clinical …

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical …

N Murray, P Coy, JL Pater, I Hodson… - Journal of Clinical …, 1993 - ascopubs.org
PURPOSE The importance of the timing of thoracic irradiation (TI) in the combined modality
therapy of limited-stage small-cell lung cancer (SCLC) was assessed in a randomized trial …